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1. Definition of stem cells
Stem cells are cells that can replicate and form one or
more differentiated cell types.
1.1. Progenitor stem cells; resulting in the differentia-
tion of a single cell type (ex. spermatogonial cells result-
ing in spermatozoa).
1.2. Multipotent stem cells; resulting in several cell
types constituting a specific tissue or organ (ex. skin stem
cells, haematopoietic stem cells, neural stem cells).
1.3. Pluripotent stem cells; resulting in all different
cell types in vitro. However, they are not able on their
own to form a whole embryo.
Cells isolated from primordial germ cells in the foetus
are embryonic germ cells. Cells isolated from the inner
cell mass at a blastocyst-stage of the embryo are embry-
onic stem cells.
1.4. Totipotent stem cells; having still the ability to give
rise to a whole embryo. In humans this ability is pre-
served until the 8 cell stage.
Characteristics of the different stem cells.
Progenitor and multipotent stem cells are present
throughout life. However they are more abundant in the
foetus than in the adult (see haematopoietic cells in the
cord blood). It is thought that pluripotent stem cells are
not present after the embryonic stage of development.
However it has recently been found that thyroid cells
from fetal or embryonic origin were present in the thy-
roid of a women with thyroiditis, years after pregnancy.
2. Source of stem cells
2.1. Stem cells of adult origin.
Progenitor and multipotent stem cells are present in
adults.
Somatic stem cells can generate for example liver, pan-
creas, bone, cartilage, neural system cells.
Haematopoietic stem cells are present in the blood,
originating from the bone marrow after stimulation.
2.2. Stem cells of fetal origin.
– Haematopoietic stem cells are present in umbilical
cord blood.
– Multipotent and pluripotent stem cells can be obtain-
ed from the fetus after termination of pregnancy.
2.3. Stem cells of embryonic origin.
Pluripotent embryonic stem cells can be obtained from
an embryo at the blastocyst stage. The embryo can be
produced by in vitro fertilisation or by transfer of an adult
nucleus to an enucleated oocyte (somatic cell nuclear
transfer).
3. Human embryonic development
3.1. At two or three days after fertilisation, an embryo
consists of identical cells which are totipotent. That is to
say that each could give rise to an embryo on its own
producing for example identical twins or quadruplets.
They are totally unspecialised and have the capacity to
differentiate into any of the cells which will constitute
the fetus as well as the placenta and membranes around
the fetus.
3.2. At four or five days after fertilisation (morula
stage), the embryo is still made up of unspecialised em-
bryonic cells, but these cells can no longer give rise to
an embryo on their own.
3.3. At five to seven days after fertilisation (blasto-
cyst stage), a hollow appears in the centre of the morula,
and the cells constituting the embryo start to be differen-
tiated into inner and outer cells:
– The outer cells will constitute the tissues around the
fetus (trophoblast), including the placenta.
– The inner cells (20 to 30 cells) will give rise to the
fetus itself as well as to some of the surrounding
tissues. If these inner cells (embryoblast) are isolat-
ed and grown in the presence of certain chemical
substances (growth factors), pluripotent embryonic
stem cells can be derived. These embryonic stem
cells are pluripotent, not totipotent since they can-
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not develop into an embryo on their own. If they are
transferred to a uterus, they would neither implant
nor develop into an embryo.
4. Research on animals
4.1. Embryonic stem cells.
For the last two decades research on embryonic stem
cells has been performed in vitro. Embryonic stem cells
need differentiation in vitro before they can be used for
therapeutic purpose. Some success has been demonstrat-
ed in the treatment of traumatic spine injury and myo-
cardial injury.
4.2. Recently it has been shown that so called »adult«
stem cells have more malleability than previously be-
lieved. Mouse neural stem cells can, in specific conditions
of culture, form cells of other organs (blood, muscle,
intestine, liver, heart). Moreover marrow stromal cells
have been shown to generate astrocytes and myocytes.
5. The therapeutic use of human stem cells
5.1. Neural stem cells.
Clinical trials in patients with Parkinsons disease have
been performed. Transplantation of neural cells derived
from the human fetus has been used and shows a thera-
peutic effect. This procedure is still experimental; five
to six aborted fetuses are necessary to provide enough
neural tissue to treat one patient with Parkinsons dis-
ease. Proliferation in culture of these neural cells is nec-
essary to provide a large amount of cells, needed for trans-
plantation.
5.2. Haematopoietic stem cells.
Adult haematopoietic stem cells can be derived from
bone marrow of donors, or from the patients themselves
(before chemotherapy). They can also be obtained from
the peripheral blood, after treatment to induce the pas-
sage of stem cells from the bone marrow into the blood
circulation.
Haematopoietic stem cells of fetal origin are obtained
from the cord blood.
These cells are preserved in cord blood banks.
They are collected immediately after birth of the
newborn and before the delivery of the placenta,
without interfering with the usual procedure of cord
clamping.
Currently an international network of banks for stem
cells from cord blood for allogenic transplantations is
developed. Also targeted transplantations are performed
where cord blood is used for first degree relatives, and
even autologous banking is propagated to be used like a
special form of »private life« insurance.
5.3. Perspectives for the future.
Production of specific cell lines for therapeutic trans-
plantation is considered as an important step to cure con-
genital or acquired lesions in human tissues; often re-
ferred to as »regenerative medicine«. Results of cell ther-
apy in animals are promising, but as yet not applicable
for clinical use.
Embryonic or fetal stem cells are less rejected com-
pared to adult stem cells. Tissues derived from allogenic
human stem cells will have the problem of rejection.
This can be avoided by the use of autologous stem
cells from adult tissue (or in principle autologous cord
blood). It is also possible to create an embryo with ge-
netic characteristics of the receptor, using somatic cell
nuclear transfer (therapeutic cloning).
6. Ethical considerations
6.1. The philosophical and religious views on the use
of embryonic stem cells in therapeutic research have been
well documented in the Unesco document of the Divi-
sion of Human Sciences, Philosophy and the Ethics of
Science and Technology (Bio 7/00/GT – 1/2, April 2001).
6.2. There has been an intense debate about the moral
status of the human embryo, which has not lead to a gen-
eral European consensus. There are two major approaches
to formulate the value of human life: first, absolute dig-
nity, respect and protection to all human life; second,
relative dignity, respect and protection to human life,
differing and depending on the development, environ-
ment and interests.
6.3. The human embryo possesses dignity and de-
serves respect and protection. This respect and protec-
tion are not absolute, but gradual, as accepted by a large
majority, since it is agreed that spare embryos, not re-
trieved for reproduction, may be destroyed.
6.4. Human embryonic cells have the potential of treat-
ing congenital and acquired diseases in the human (re-
generative medicine). Research on human embryonic
stem cells may be necessary if this treatment in the hu-
man is to succeed.
6.5. Stem cells isolated from the blastocyst no longer
by themselves have the ability to develop into a human
being. However these cells should be handled respect-
fully like any human tissue.
6.6. The moral principles that apply to the use of spare
embryos resulting from infertility treatments are differ-
ent from those embryos created specially for research or
for therapeutic use by somatic nuclear transfer method-
ology (therapeutic cloning).
6.7. It is necessary that any research on human em-
bryos, embryonic tissues and human stem cells should
be approved by Research Ethics Committees.
7. E.B.C.O.G. recommendation
7.1. The use of adult stem cells should be treated in
the same way as any other tissue (organs and blood) do-
nation, based on respect for the integrity of the human
body and the free and informed consent of the donor.
7.2. The use of haematopoietic stem cells from the cord
blood after birth of the newborn requires informed con-
sent regarding possible uses of cells by the donor (wom-
an or couple).
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7.3. The use of fetal stem cells requires free and in-
formed consent from the woman or couple. The condi-
tions of legal abortion should not be changed for the
purpose of obtaining fetal tissues. When termination of
pregnancy is carried out, the timing and method used
might not be influenced by the need to retrieve fetal tis-
sue.
7.4. In some European countries the creation of »spare
embryos« is permitted. When decided that spare embryos
will be destroyed it is accepted that after thawing further
in vitro culture is performed, to produce blastocysts to
retrieve embryonic stem cells for research.Free and in-
formed consent from the woman or couple is required
when these spare embryos are used for obtaining embry-
onic stem cells.
7.5. In most European countries the creation of em-
bryos for research is not permitted; it is assumed that
this is in major conflict with the priority of human digni-
ty. If somatic cell nuclear transfer proves effective for
»regenerative medicine«, it may be acceptable in the fu-
ture that embryos are created for this purpose, under strict
regulations.
7.6 Reproductive cloning shows severe ethical prob-
lems regarding human dignity. Furthermore given the
high risk of abnormalities, the scientific objections to
human cloning are currently overwhelming. Therefore
reproductive cloning in the human should be forbidden.
7.7. Research on stem cells should include research
on adult stem cells, embryonic, fetal and cord blood stem
cells.
7.8. The use of stem cells needs strict regulations.
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